The Icahn School of Medicine at Mount Sinai has been selected to be one of a handful of medical centers taking part in Stem Cell Inc.’s research study. This is a phase II pathway evaluating the potential of neural stem cells to treat cervical spinal cord injury (cSCI).
What is the Pathway study?
The purpose of the Pathway Study is to evaluate the safety and potential benefit of neural stem cell transplantation for people with cSCI. If you are eligible for the study and if you choose to participate, your participation will last approximately 12 months.
Who can participate?
You may be able to join the study if you are between 18 to 60 years old, have a cervical spinal cord injury that is classified as AIS grade A, B, or C, been less than two years since your injury occurred and more than 4 weeks, and are generally in good health.
To find out if you may be eligible to participate, please contact:
Alex Voigt Alexandra.voigt@mountsinai.org 212-824-8379
